Cardior Pharmaceuticals GmbH has closed a €64m series B financing round that will help the German biotech take its non-coding RNA candidate into mid-stage trials for heart failure.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?